On 4 August, Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced positive clinical study results from the Company’s Phase I trial of PRX-106, an orally administered plant cell-expressed recombinant anti-TNF fusion protein. PRX-106 demonstrated a favorable safety and tolerability profile and biological activity in the gut. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) belongs to Healthcare sector. Its weekly performance is 3.77%. On last trading day company shares ended up $1.65. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) distance from 50-day simple moving average (SMA50) is -13.97%.
Pixelworks, Inc. (NASDAQ: PXLW) announced that it plans to offer shares of its common stock in a public offering registered with the U.S. Securities and Exchange Commission. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Pixelworks, Inc. (NASDAQ:PXLW) shares decreased -4.67% in last trading session and ended the day at $5.51. PXLW Gross Margin is 49.10% and its return on assets is -30.80%. Pixelworks, Inc. (NASDAQ:PXLW) quarterly performance is 27.25%.
Fluidigm (NASDAQ: FLDM) reported Q2 EPS of ($0.53), $0.05 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $30.43 million. Fluidigm is projecting total revenue to be between $110 million and $115 million versus prior guidance of between $133 million and $143 million.On 06 August, Fluidigm Corporation (NASDAQ:FLDM) shares decreased -0.35% and was closed at $19.93. FLDM EPS growth in last 5 year was 29.60%. Fluidigm Corporation (NASDAQ:FLDM) year to date (YTD) performance is -40.91%.
On 29 July, Rollins Inc. (NYSE:ROL) recorded second quarter revenues of $392.2 million, an increase of 6.2% over the prior year’s second quarter of $369.4 million. Net income increased 10.3% to $45.1 million or $0.21 per diluted share for the second quarter ended June 30, 2015 compared to $40.9 million or $0.19 per diluted share for the same period in 2014. Rollins Inc. (NYSE:ROL) ended the last trading day at $29.45. Company weekly volatility is calculated as 2.38% and price to cash ratio as 58.69. Rollins Inc. (NYSE:ROL) showed a weekly performance of 0.31%.
Zacks upgraded shares of FLIR Systems (NASDAQ:FLIR) from a sell rating to a hold rating in a report released on Monday, MarketBeat Ratings reports. FLIR Systems, Inc. (NASDAQ:FLIR) shares remains unchanged in last trading session and ended the day at $30.75. FLIR Gross Margin is 50.40% and its return on assets is 9.50%. FLIR Systems, Inc. (NASDAQ:FLIR) quarterly performance is -1.35%.